0001493152-23-044898.txt : 20231214 0001493152-23-044898.hdr.sgml : 20231214 20231214170339 ACCESSION NUMBER: 0001493152-23-044898 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231214 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231214 DATE AS OF CHANGE: 20231214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sonnet BioTherapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001106838 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 522102141 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35570 FILM NUMBER: 231487820 BUSINESS ADDRESS: STREET 1: 100 OVERLOOK CENTER STREET 2: SUITE 102 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-375-2227 MAIL ADDRESS: STREET 1: 100 OVERLOOK CENTER STREET 2: SUITE 102 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: Chanticleer Holdings, Inc. DATE OF NAME CHANGE: 20050510 FORMER COMPANY: FORMER CONFORMED NAME: TULVINE SYSTEMS INC DATE OF NAME CHANGE: 20000214 8-K 1 form8-k.htm
false 0001106838 0001106838 2023-12-14 2023-12-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 14, 2023

 

SONNET BIOTHERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35570   20-2932652

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

100 Overlook Center, Suite 102    
Princeton, New Jersey   08540
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (609) 375-2227

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 Par Value   SONN   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On December 14, 2023, Sonnet BioTherapeutics Holdings, Inc. (the “Registrant”) issued a press release regarding its financial results for the fiscal year ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

 

Forward-Looking Statements

 

This report, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements typically are identified by use of terms such as “may,” “will,” “should,” “plan,” “expect,” “anticipate,” “estimate” and similar words, and the opposites of such words, although some forward-looking statements are expressed differently. Forward-looking statements involve known and unknown risks and uncertainties that exist in the Registrant’s operations and business environment, which may be beyond the Registrant’s control, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. For example, forward-looking statements include, without limitation: statements regarding prospects for additional customers; market forecasts; projections of earnings, revenues, synergies, accretion or other financial information; and plans, strategies and objectives of management for future operations. The risks and uncertainties referred to above include, but are not limited to, risks detailed from time to time in the Registrant’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended September 30, 2023. These risks could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Registrant. Forward-looking statements represent the judgment of management of the Registrant regarding future events. Although the Registrant believes that the expectations reflected in such forward-looking statements are reasonable at the time that they are made, the Registrant can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable law, the Registrant assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Exhibit
     
99.1   Press Release, dated December 14, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Sonnet BioTherapeutics Holdings, Inc.
  a Delaware corporation
  (Registrant)
     
Date: December 14, 2023 By: /s/ Pankaj Mohan, Ph.D.
  Name: Pankaj Mohan, Ph.D.
  Title: Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

 

PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs focused on oncology, announced today its financial results for the fiscal year ended September 30th, 2023 and provided a business update.

 

“Sonnet has had a very productive year, exemplified by important achievements across our pipeline. The successful completion of the Phase 1 SB102 study with SON-1010 in healthy volunteers, combined with the initial data reported from the Phase 1 SB101 study in cancer patients propelled us forward into receiving FDA Investigational New Drug (IND) acceptance for the Phase 1b/2a SB221 combination study of SON-1010 with Roche’s atezolizumab, in platinum-resistant ovarian cancer (PROC),” commented Pankaj Mohan, Ph.D., Founder and CEO. “Our efforts to advance our pipeline continue and are accompanied by Janssen’s ongoing evaluation of SON-1010, SON-1210 and SON-1410 in combination with certain proprietary cell therapy assets. We are also working diligently to complete enrollment of the first portion of the Phase 1b SB211 study of SON-080 in chemotherapy-induced peripheral neuropathy (CIPN), with the hope of having early safety data available during the first quarter of 2024. We also expect to be able to share safety data from the SB102 and SB221 studies of SON-1010 during the first half of the year. In all, 2024 should be another exciting year for the company.”

 

Fiscal Year 2023 and Recent Corporate Updates

 

Announced Collaboration Agreement with Roche: On January 9, 2023, Sonnet announced a collaboration agreement with Roche for the clinical evaluation of SON-1010 with atezolizumab. The companies have entered into a Master Clinical Trial and Supply Agreement (MCSA), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (PROC) patient setting. Further, the companies will provide SON-1010 and atezolizumab, respectively, for use in the Phase 1b/Phase 2a combination safety, dose-escalation, and efficacy study (SB221). On August 16, Sonnet announced that the FDA accepted the Investigational New Drug application (IND) for the use of SON-1010 in ovarian cancer, authorizing the companies to move forward with the SB221 trial.

 

Sonnet is pleased to provide the following updates on its pipeline assets:

 

SON-1010 (IL12-FHAB): In January 2023, Sonnet announced data from SB102, a single-ascending dose (SAD) Phase 1 clinical trial designed to carefully study the pharmacokinetics (PK) and pharmacodynamics (PD) of SON-1010 in preparation for combination studies. Typical dose-related increases were seen with SON-1010 in the serum after subcutaneous (SC) administration. Drug levels peaked at about 11 hours and the mean elimination half-life (t½) after the 150 ng/kg dose of SON-1010 was 112 hours, compared to 12 hours for rhIL-12 given SC, as reported in the literature.

 

 
 

 

In April, Sonnet presented additional data from the SB101 study of SON-1010 at the 2023 AACR Annual Meeting. SB101 is a SAD trial in adult patients with advanced solid tumors that commenced in the second quarter of 2022 and is currently enrolling the final dose cohort. Of the 15 patients from SB101 who were evaluable for follow-up at this latest cutoff, 9 had stable disease at the first follow-up scan, 4 of which were already progressing at study entry. At the four-month follow-up, 5 of 14 patients remained stable at the second scan, suggesting clinical benefit of SON-1010 in 36% of patients. As an example, the first patient dosed, who has an aggressive endometrial sarcoma, had target tumor shrinkage with complete resolution of ascites at one point and has been clinically stable for over a year. SON-1010 has been safe and tolerable at all doses tested to date. Adverse events have generally been mild/moderate and transient in nature, with no study discontinuations for safety reasons. In addition, adverse effects have been less numerous and less intense with subsequent doses. Comparison of the PK curves between the two studies suggests that SON-1010 may be targeting tumors, as it was designed to do. Cytokine analysis following each dose revealed controlled and prolonged induction of interferon gamma (IFNγ) that peaked at 24 to 48 hours and returned to baseline after 2 to 4 weeks, which may improve tumor control. A small increase in IL-10 was observed with each dose, as might be expected in response to IFNγ. There was either a minimal or no signal for IL-1β, IL-6, IL-8, and TNFα and no indication of any potential for cytokine release syndrome (CRS) at these doses. Safety data from final dose escalation in the SB101 study are expected during the first half of 2024.

 

Following FDA acceptance of the IND in August, Sonnet launched the SB221 study with several patients currently being dosed. This trial consists of a modified 3+3 dose-escalation design in Part 1 to establish the maximum tolerated dose (MTD) of SON-1010 with a fixed dose of atezolizumab. Clinical benefit in PROC will be confirmed in an expansion group to establish the recommended Phase 2 dose. Part 2 of the study will then investigate SON-1010 monotherapy, its use in combination with atezolizumab, or the standard of care (SOC) for PROC in a randomized comparison to show proof-of-concept (POC). Initial safety data from Part 1 of the SB221 study are expected during the first half of 2024.

 

In September 2023, Sonnet announced the completion of two independent in vivo proof-of-concept (POC) studies to show the biodistribution of interleukin-FHAB molecules to the tumor microenvironment (TME), using labs with expertise in radiolabeling biologics and in vivo biodistribution analysis. The labs employed different radiolabeling methodologies (99mTc or 89Zr) for mIL-12 and mIL12-FHAB. The two studies were completed using the B16F10 mouse melanoma model to measure the accumulation of radiolabeled product and tumor volume inhibition over various time points. Both studies indicated that mIL12-FHAB had significantly higher tumor accumulation, 2.5-4.7 times higher on average at the longer time points, and increased retention when compared to mIL-12. Accumulation was demonstrated in tumors compared to normal mice, and was transient in liver, kidney, and other organs, as expected. Importantly, radiolabeled mIL12- FHAB also demonstrated measurable accumulation in the draining lymph nodes. Overall, these findings have important implications for therapeutic applications of any mono-(ILx-FHAB) or bi-functional (ILx-FHAB -ILy) molecules demonstrating enhanced tumor targeting and accumulation, as well as the potential for improved efficacy that could lead to a variety of drug candidates.

 

SON-1210 (IL12-FHAB-IL15): In February 2023, Sonnet announced data from two successfully completed IND-enabling toxicology studies with SON-1210 in non-human primates. The compound elicited no serious adverse events in repeat, subcutaneous dosing and was well-tolerated using dosing levels at least 50x higher than the highest anticipated human clinical dose level. Sonnet is prepared to initiate the regulatory authorization process for SON-1210, pending the outcome of any partnering activity.

 

 
 

 

SON-1410 (IL18-FHAB-IL12): Cell line development and process development are ongoing, with early experimental drug supply suitable for formulation and analytical method development activities. After some delays in 2023, activities will continue into 2024 with the potential to generate a drug suitable for preclinical studies and subsequent human studies.

 

SON-080 (low-dose IL-6): Enrollment of the first portion of the SB211 study in CIPN is nearing completion, which should position the DSMB to complete its review of the preliminary safety data during the first calendar quarter of 2024.

 

John Cini, Ph.D., Sonnet’s CSO and Co-founder commented on the fiscal year’s R&D accomplishments, saying, “The biodistribution data we announced in September further confirmed the ability of the FHAB technology to extend therapeutic half-life and potentiate tumor targeting, which, combined with the clinical data we presented at AACR in April, position the platform as a differentiated approach for developing next-generation, cytokine-based oncologic drugs. We are excited about the opportunity to continue to highlight our pipeline assets at upcoming medical conferences and through the publication of peer-reviewed articles that elucidate our findings.”

 

Financings Completed: On February 10, 2023, we closed a public offering of common stock and certain warrants for net proceeds of $13.6 million through the issuance and sale of 530,222 shares of our common stock and, to certain investors, pre-funded warrants to purchase 101,090 shares of common stock, and accompanying common warrants to purchase up to an aggregate of 1,262,618 shares of our common stock. The public offering price of each share of common stock (or pre-funded warrant in lieu thereof) and accompanying common warrant was $23.76.

 

On June 30, 2023, we closed a registered direct offering of common stock (and common stock equivalents in lieu thereof) and a concurrent private placement of certain common stock warrants for net proceeds of $1.9 million through the issuance and sale of 166,363 shares of our common stock and, to certain investors, pre-funded warrants to purchase 60,909 shares of common stock, and accompanying common warrants to purchase up to an aggregate of 227,272 shares of our common stock. The offering price of each share of common stock (or pre-funded warrant in lieu thereof) and accompanying common warrant was $9.90.

 

On October 26, 2023, we closed a public offering of common stock and certain warrants for net proceeds of $4.1 million through the issuance and sale of 1,306,250 shares of our common stock and, to certain investors, pre-funded warrants to purchase 1,537,500 shares of common stock and accompanying common warrants to purchase up to an aggregate of 5,687,500 shares of our common stock. The public offering price of each share of common stock (or pre-funded warrant in lieu thereof) and accompanying common warrant was $1.60.

 

Fiscal Year Ended September 30, 2023 Financial Results

 

Jay Cross, CFO, elaborated on Sonnet’s performance, saying, “We are very pleased with the progress we made this year in an otherwise challenging environment for small biotechnology companies. We will continue to closely monitor our operating expenses, and we are happy to share the preliminary approval we recently received to sell up to $4.8 million of our New Jersey state net operating losses.”

 

 
 

 

As of September 30, 2023, Sonnet had no debt and $2.27 million cash on hand, which excludes net proceeds of $4.1 million from the October financing. Sonnet believes its cash at September 30, 2023, together with the $4.1 million net proceeds from the October financing, will fund its projected operations into March 2024. In addition, Sonnet expects to receive a $0.8 million net cash refund from the research and development tax incentive program in Australia and recently received preliminary approval of its application to sell up to $4.8 million of its New Jersey state net operating losses through the Technology Business Tax Certificate Transfer Program, subject to execution of such sale, which together Sonnet believes will extend the funding of its projected operations into the third calendar quarter of 2024.

 

Research and development expenses were $11.8 million for the year ended September 30, 2023, compared to $21.4 million for the year ended September 30, 2022. The decrease of $9.6 million was primarily due to the establishment of cost savings by transitioning product development activities to cost advantaged locations such as India and Australia, by reducing expenditures on tertiary programs such as SON-3015, which has been placed on a development hold, and suspending antiviral development related to SON-1010, as well as a decrease in share-based compensation expense.

 

General and administrative expenses were $7.1 million for the year ended September 30, 2023, compared to $8.6 million for the year ended September 30, 2022. The decrease of $1.5 million relates primarily to a decrease in share-based compensation, legal and business development expenses, as we are managing expenses for liquidity purposes and are tightening our focus on the research and development projects we have assessed to have the greatest near-term potential.

 

About Sonnet BioTherapeutics Holdings, Inc.

 

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. Sonnet’s FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.

 

Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

 

Forward-Looking Statements

 

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s cash runway, the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Sonnet BioTherapeutics Investor Contact:

 

Jack Yauch

Solebury Strategic Communications

862-754-1024

jyauch@soleburystrat.com

 

 
 

 

Sonnet BioTherapeutics Holdings, Inc.

Consolidated Balance Sheets

 

   September 30, 
   2023   2022 
Assets          
Current assets:          
Cash and cash equivalents  $2,274,259   $3,052,879 
Prepaid expenses and other current assets   1,677,396    1,643,743 
Income tax receivable   786,574    717,305 
Total current assets   4,738,229    5,413,927 
Property and equipment, net   33,366    46,211 
Operating lease right-of-use asset   193,689    256,594 
Deferred offering costs   49,988    113,280 
Other assets   414,206    — 
Total assets  $5,429,478   $5,830,012 
Liabilities and stockholders’ deficit          
Current liabilities:          
Related party notes  $—   $748 
Accounts payable   2,201,999    4,752,340 
Accrued expenses and other current liabilities   3,230,922    3,193,972 
Current portion of operating lease liability   73,048    51,328 
Deferred income   18,626    166,431 
Total current liabilities   5,524,595    8,164,819 
Operating lease liability, net of current portion   130,863    203,912 
Total liabilities   5,655,458    8,368,731 
Commitments and contingencies          
Stockholders’ deficit:          
Common stock, $0.0001 par value: 125,000,000 shares authorized; 1,750,426 and 251,955 issued and outstanding at September 30, 2023 and 2022, respectively   175    25 
Additional paid-in capital   110,017,598    88,872,315 
Accumulated deficit   (110,243,753)   (91,411,059)
Total stockholders’ deficit   (225,980)   (2,538,719)
Total liabilities and stockholders’ deficit  $5,429,478   $5,830,012 

 

See 10-K filed today for notes to consolidated financial statements

 

 
 

 

Sonnet BioTherapeutics Holdings, Inc.

Consolidated Statements of Operations

 

   Years ended September 30, 
   2023   2022 
Collaboration revenue  $147,805   $349,943 
Operating expenses:          
Research and development   11,814,690    21,444,019 
General and administrative   7,125,732    8,575,283 
Total operating expense   18,940,422    30,019,302 
Loss from operations   (18,792,617)   (29,669,359)
           
Foreign exchange loss   (40,077)   (52,482)
Net loss  $(18,832,694)  $(29,721,841)
Per share information:          
Net loss per share, basic and diluted  $(18.14)  $(150.52)
Weighted average shares outstanding, basic and diluted  $1,038,188   $197,462 

 

See 10-K filed today for notes to consolidated financial statements

 

SOURCE: Sonnet BioTherapeutics Holdings, Inc.

 

 

 

 EX-101.SCH 3 sonn-20231214.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sonn-20231214_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 sonn-20231214_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Dec. 14, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 14, 2023
Entity File Number 001-35570
Entity Registrant Name SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Entity Central Index Key 0001106838
Entity Tax Identification Number 20-2932652
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Overlook Center
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code (609)
Local Phone Number 375-2227
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 Par Value
Trading Symbol SONN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001106838 2023-12-14 2023-12-14 iso4217:USD shares iso4217:USD shares false 0001106838 8-K 2023-12-14 SONNET BIOTHERAPEUTICS HOLDINGS, INC. DE 001-35570 20-2932652 100 Overlook Center Suite 102 Princeton NJ 08540 (609) 375-2227 false false false false Common Stock, $0.0001 Par Value SONN NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sonnetbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm sonn-20231214.xsd sonn-20231214_lab.xml sonn-20231214_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "SONN", "nsuri": "http://sonnetbio.com/20231214", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "sonn-20231214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "sonn-20231214_lab.xml" ] }, "presentationLink": { "local": [ "sonn-20231214_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://sonnetbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-23-044898-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-044898-xbrl.zip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